QIAGEN EBITDA 2010-2023 | QGEN
QIAGEN annual and quarterly EBITDA history from 2010 to 2023. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- QIAGEN EBITDA for the quarter ending March 31, 2023 was $0.157B, a 41.38% decline year-over-year.
- QIAGEN EBITDA for the twelve months ending March 31, 2023 was $0.663B, a 27.86% decline year-over-year.
- QIAGEN 2022 annual EBITDA was $0.774B, a 11.83% decline from 2021.
- QIAGEN 2021 annual EBITDA was $0.877B, a 38.43% increase from 2020.
- QIAGEN 2020 annual EBITDA was $0.634B, a 157.54% increase from 2019.
QIAGEN Annual EBITDA
(Millions of US $) |
| 2022 |
$774 |
| 2021 |
$877 |
| 2020 |
$634 |
| 2019 |
$246 |
| 2018 |
$509 |
| 2017 |
$395 |
| 2016 |
$332 |
| 2015 |
$391 |
| 2014 |
$378 |
| 2013 |
$263 |
| 2012 |
$368 |
| 2011 |
$267 |
| 2010 |
$331 |
| 2009 |
$301 |
QIAGEN Quarterly EBITDA
(Millions of US $) |
| 2023-03-31 |
$157 |
| 2022-12-31 |
$168 |
| 2022-09-30 |
$156 |
| 2022-06-30 |
$181 |
| 2022-03-31 |
$268 |
| 2021-12-31 |
$232 |
| 2021-09-30 |
$193 |
| 2021-06-30 |
$224 |
| 2021-03-31 |
$227 |
| 2020-12-31 |
$224 |
| 2020-09-30 |
$107 |
| 2020-06-30 |
$178 |
| 2020-03-31 |
$126 |
| 2019-12-31 |
$143 |
| 2019-09-30 |
$-141 |
| 2019-06-30 |
$132 |
| 2019-03-31 |
$113 |
| 2018-12-31 |
$148 |
| 2018-09-30 |
$134 |
| 2018-06-30 |
$117 |
| 2018-03-31 |
$109 |
| 2017-12-31 |
$105 |
| 2017-09-30 |
$122 |
| 2017-06-30 |
$84 |
| 2017-03-31 |
$84 |
| 2016-12-31 |
$66 |
| 2016-09-30 |
$107 |
| 2016-06-30 |
$87 |
| 2016-03-31 |
$72 |
| 2015-12-31 |
$115 |
| 2015-09-30 |
$101 |
| 2015-06-30 |
$89 |
| 2015-03-31 |
$86 |
| 2014-12-31 |
$88 |
| 2014-09-30 |
$102 |
| 2014-06-30 |
$97 |
| 2014-03-31 |
$91 |
| 2013-12-31 |
$88 |
| 2013-09-30 |
$85 |
| 2013-06-30 |
$15 |
| 2013-03-31 |
$74 |
| 2012-12-31 |
$103 |
| 2012-09-30 |
$89 |
| 2012-06-30 |
$94 |
| 2012-03-31 |
$82 |
| 2011-12-31 |
$27 |
| 2011-09-30 |
$77 |
| 2011-06-30 |
$85 |
| 2011-03-31 |
$77 |
| 2010-12-31 |
$89 |
| 2010-09-30 |
$50 |
| 2010-06-30 |
$43 |
| 2010-03-31 |
$79 |
| 2009-12-31 |
$69 |
| 2009-09-30 |
$53 |
| 2009-06-30 |
$51 |
| 2009-03-31 |
$68 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$10.584B |
$2.142B |
|
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
|
